论文部分内容阅读
目的:采用随机、对照方法,比较组胺H1受体拮抗剂氯雷他定和白三烯受体拮抗剂异丁司特治疗类固醇抵抗性变应性鼻炎的疗效和安全性。方法:异丁司特组35例,氯雷他定组34例,采用记分方法比较2种药物对临床症状和体征的缓解。结果:异丁司特对临床症状总积分和体征总积分的改善程度显著优于氯雷他定(P<0.05);单因素方差分析:异丁司特组治疗后3、7、14 d的症状和体征的记分显著低于治疗前(P<0.01),且无明显不良反应。结论:异丁司特能有效缓解类固醇抵抗性变应性鼻炎的临床症状和体征,有可靠的疗效和安全性,对类固醇抵抗性变应性鼻炎患者不能采取加大类固醇剂量或延长疗程的方法,可采用白三稀受体拮抗剂——异丁司特治疗。
OBJECTIVE: To compare the efficacy and safety of loratadine, a histamine H1 receptor antagonist, and ibudilastin, a leukotriene receptor antagonist, in the treatment of steroid-resistant allergic rhinitis using a randomized, controlled trial. Methods: 35 patients in the ibudilast group and 34 patients in the loratadine group were enrolled in this study. The clinical symptoms and signs of the two drugs were compared by scoring method. Results: The improvement of clinical symptom score and total score of ibudilast was significantly better than loratadine (P <0.05). One-way analysis of variance (ANOVA) showed that 3, 14 and 14 days after treatment with ibudilast Symptoms and signs were significantly lower than before treatment (P <0.01), and no significant adverse reactions. Conclusion: Ibudiustine can effectively relieve the clinical symptoms and signs of steroid-resistant allergic rhinitis, and has reliable curative effect and safety. The steroid-resistant allergic rhinitis patients can not take steroid dose or extend the course of treatment , Can be white three receptor antagonist - ibudilast treatment.